Insilico Medicine's generative AI platform was credited in a press release with "discovering" a promising pulmonary-fibrosis drug, but the company's patent named five human inventors, including CEO Alex Zhavoronkov, and did not mention AI.
Notes on verification
Confirmed by original MIT Technology Review investigative article and corroborated by multiple independent outlets reporting the same underlying facts about Insilico Medicine's press release vs. patent filing. [tier=unverified indep_score=0.3 clusters=3 claim_tier=notable] [rescored 2026-09-15: curated origin-host map (PR #65); unclassified hosts no longer scored as aggregators]
Sources
- MIT Technology Review (seed:technology_and_ai)
- https://www.artiverse.ca/the-five-human-names-behind-an-ai-designed-drug/ (corroboration)
- https://ramaonhealthcare.com/when-ai-designs-a-drug-who-gets-the-credit/ (corroboration)
- https://www.rajashreerajadhyax.com/post/when-ai-discovers-the-molecule-who-owns-the-invention (corroboration)